 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors. [1] It has neuroprotective effects in animal studies, [2] and has been used as a lead compound to find further potent derivatives. [3]
See also
References
- ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi: 10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
- ^ Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (April 2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 16–27. CiteSeerX 10.1.1.420.2457. doi: 10.1124/jpet.103.061655. PMID 14722323. S2CID 7730290.
- ^ Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, et al. (May 2008). "Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands". The Journal of Organic Chemistry. 73 (9): 3497–507. doi: 10.1021/jo800028q. PMID 18363376.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |